Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.10.0.1
Stockholders' Equity
9 Months Ended
Sep. 30, 2018
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
9.
Stockholders’ Equity
 
Stock-Based Compensation
 
On May 7, 2018, in connection with the closing of the sale under the APA of substantially all of the Company’s assets to Cellularity, which triggered certain change in control provisions of the Company’s equity plans, all unvested and outstanding options and restricted stock awards under the 2011 Plan and 2014 Plan became vested and exercisable.
 
A summary of the stock option activity for the nine months ended September 30, 2018 is presented below (in thousands, except years and per option data):
 
 
 
Number of O
ptions
 
 
Weighted
Average
Exercise
Price per 
Option
 
 
Weighted 
Average 
Remaining
Life in 
Years
 
 
Intrinsic Value
 
Outstanding, December 31, 2017
 
 
810
 
 
$
52.90
 
 
 
 
 
 
 
 
 
  Granted
 
 
-
 
 
 
-
 
 
 
 
 
 
 
 
 
  Exercised
 
 
-
 
 
 
-
 
 
 
 
 
 
 
 
 
  Forfeited
 
 
(466
)
 
 
34.68
 
 
 
 
 
 
 
 
 
Outstanding, September 30, 2018
 
 
344
 
 
$
46.54
 
 
 
4.8
 
 
$
-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exerciseable, September 30, 2018
 
 
344
 
 
$
46.54
 
 
 
4.8
 
 
$
-
 
 
As a result, a summary of the Company’s outstanding and exercisable options as of September 30, 2018 was as follows (in thousands, except per share data):
 
 
 
Options Outstanding
 
 
Options Exercisable
 
 
 
 
Range of

Exercise Price
 
Weighted

Average

Exercise

Price
 
 
Outstanding

Number of

Options
 
 
Weighted Average

Exercise Price
 
 
Weighted

Average

Remaining

Life in Years
 
 
Exercisable

Number of

Options
 
$2.00 - $4.00
 
$
3.63
 
 
 
54
 
 
 
3.63
 
 
 
8.4
 
 
 
54
 
$4.10 - $9.90
 
 
8.72
 
 
 
23
 
 
 
8.72
 
 
 
7.6
 
 
 
23
 
$10.00 - $19.90
 
 
10.77
 
 
 
11
 
 
 
10.77
 
 
 
5.8
 
 
 
11
 
$20.00 - $39.90
 
 
33.47
 
 
 
40
 
 
 
33.47
 
 
 
4.6
 
 
 
40
 
$40.00 - $49.90
 
 
44.71
 
 
 
27
 
 
 
44.71
 
 
 
4.0
 
 
 
27
 
$50.00 - $59.90
 
 
53.87
 
 
 
26
 
 
 
53.87
 
 
 
1.5
 
 
 
26
 
$60.00 - $69.90
 
 
66.23
 
 
 
135
 
 
 
66.23
 
 
 
4.2
 
 
 
135
 
$70.00 - $79.90
 
 
79.40
 
 
 
1
 
 
 
79.40
 
 
 
5.6
 
 
 
1
 
$80.00 - $89.90
 
 
87.50
 
 
 
11
 
 
 
87.50
 
 
 
2.9
 
 
 
11
 
$90.00 - $99.90
 
 
90.00
 
 
 
11
 
 
 
90.00
 
 
 
3.0
 
 
 
11
 
$100.00 - $266.90
 
 
109.40
 
 
 
5
 
 
 
109.40
 
 
 
1.6
 
 
 
5
 
 
 
 
46.54
 
 
 
344
 
 
 
46.54
 
 
 
4.8
 
 
 
344
 
 
For the three months ended September 30, 2018 and 2017, the Company recognized $0.023 million and $0.7 million of stock-based compensation expense, of which, $0.009 million and ($0.001) million is included in cost of revenues and $0.014 million and $0.7 million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. For the nine months ended September 30, 2018 and 2017, the Company recognized $1.0 million and $1.6 million of stock-based compensation expense, of which, $0.030 million and $0.025 million is included in cost of revenues and $0.97 million and $1.6 million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. As of September 30, 2018, there was no unrecognized stock-based compensation expense remaining.
 
Reverse Stock Split
 
The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 5, 2017. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share.